Europe's medicines regulator said that blood clots should be listed as a “very rare” side effect of Johnson & Johnson's coronavirus vaccine, but that the benefits of the shot still outweighed the risks, AFP reported.

After reviewing isolated cases of clotting among people who received the vaccine, EMA's safety committee said it found a “possible link” to the jab.

The regulator said its safety committee “concluded that a warning about unusual blood clots with low blood platelets should be added to the product information” for the J&J shot.

“This is a very rare effect,” EMA chief Emer Cooke told reporters. “But it also makes it very important for doctors and patients to be aware of the signs so that they can spot any concerns.”

Opinion

Editorial

Sustainable path?
Updated 13 Jun, 2026

Sustainable path?

The FY27 budget is the first clear signal that the government is ready to transition from stabilisation to growth.
Prioritising education
13 Jun, 2026

Prioritising education

THOUGH the improvement in the country’s literacy rate may be slight, as highlighted by the Economic Survey, it ...
Poverty’s rise
13 Jun, 2026

Poverty’s rise

AS attention turns to the government’s plans for the coming fiscal year, one set of figures deserves particular...
A difficult story
Updated 12 Jun, 2026

A difficult story

Unless productivity becomes the dominant target of economic policy, Pakistan will continue to oscillate between crises and fragile recovery.
Rough waters
12 Jun, 2026

Rough waters

AMONGST the key potential triggers for fresh conflict in South Asia is water. The Indian state is behaving in an...
Politicised football
12 Jun, 2026

Politicised football

ALMOST three-and-half years since Lionel Messi led Argentina to FIFA World Cup glory, the latest edition of...